Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis

Gastroenterology

Volumn 151, Issue 1, 2016, Pages 87-96.e6

  Lembo, Anthony ^a   Camilleri, Michael ^b   McCallum, Richard ^c   Sastre, Ramon ^d   Breton, Cristian ^e   Spence, Sharon ^f   White, Jeffery ^f   Currie, Michelle ^f   Gottesdiener, Keith ^f   Stoner, Elizabeth ^f  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d APF Research LLC   (United States)

^e International Research Associates   (United States)

^f Rhythm Pharmaceuticals   (United States)

Author keywords

Dose Comparison; Gastrointestinal Motility; Phase 2 Trial; RM 131

Indexed keywords

GLUCOSE; PLACEBO; RELAMORELIN; OLIGOPEPTIDE;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; AGED; ANTIBODY TITER; ARTICLE; BILE DUCT STONE; BLOATING; CAUCASIAN; CHOLECYSTITIS; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DIABETIC STOMACH PARESIS; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NEPHROLITHIASIS; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSTRUCTIVE UROPATHY; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY; SIDE EFFECT; SINGLE BLIND PROCEDURE; STOMACH EMPTYING; URINARY TRACT INFECTION; UROSEPSIS; VOMITING; WEIGHT CHANGE; COMPLICATION; DRUG EFFECTS; GASTROPARESIS; MIDDLE AGED; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GASTRIC EMPTYING; GASTROPARESIS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; TREATMENT OUTCOME; VOMITING;

EID: 84990068260     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.03.038     Document Type: Article

References (23)

1. 1 Camilleri, M., Bharucha, A.E., Farrugia, G., Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol 9 (2011), 5–12.
2. 2 Hyett, B., Martinez, F.J., Gill, B.M., et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology 137 (2009), 445–452.
3. 3 Pasricha, P.J., Yates, K.P., Nguyen, L., et al. Outcomes and factors associated with reduced symptoms in patients with gastroparesis. Gastroenterology 149 (2015), 1762–1774.
4. 4 Parkman, H.P., Yates, K., Hasler, W.L., et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol 9 (2011), 1056–1064.
5. 5 Murray, C.D., Martin, N.M., Patterson, M., et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 54 (2005), 1693–1698.
6. 6 Camilleri, M., Papathanasopoulos, A., Odunsi, S.T., Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 6 (2009), 343–352.
7. 7 Van der Ploeg, L., Laken, H., Sharma, S., et al. Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131. Life Sci 109 (2014), 20–29.
8. 8 Shin, A., Camilleri, M., Busciglio, I., et al. Randomized controlled phase Ib study of ghrelin agonist, RM 131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 36 (2013), 41–48.
9. 9 Shin, A., Camilleri, M., Busciglio, I., et al. The ghrelin agonist RM 131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol 11 (2013), 1453–1459.e4.
10. 10 Kaplan, L.M., White, J., Spence, S., et al. RM-131, a novel ghrelin analog, demonstrates potent prokinetic activity in phase 1 single- and multiple-dose studies in healthy volunteers. Am J Gastroenterol, 107, 2012, S1.
11. 11 Camilleri, M., Acosta, A., Emerging treatments in neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil 27 (2015), 324–332.
12. 12 US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Published December 2009. Accessed June 5, 2016.
13. 13 Revicki, D.A., Camilleri, M., Kuo, B., et al. Development and content validity of a gastroparesis cardinal symptom index daily diary. Aliment Pharmacol Ther 30 (2009), 670–680.
14. 14 Szarka, L.A., Camilleri, M., Vella, A., et al. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol 6 (2008), 635–643.
15. 15 Bouras, E.P., Scolapio, J.S., Gastric motility disorders: management that optimizes nutritional status. J Clin Gastroenterol 38 (2004), 549–557.
16. 16 Cherian, D., Parkman, H.P., Nausea and vomiting in diabetic and idiopathic gastroparesis. Neurogastroenterol Motil 24 (2012), 217–222.
17. 17 Acosta, A., Camilleri, M., Kolar, G., et al. Relamorelin relieves constipation and accelerates colonic transit in a phase 2, placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 13 (2015), 2312–2319.
18. 18 Ejskjaer, N., Wo, J.M., Esfandyari, T., et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 25 (2013), e140–e150.
19. 19 McCallum, R.W., Lembo, A., Esfandyari, T., et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 25 (2013), e705–e717.
20. 20 Ejskjaer, N., Dimcevski, G., Wo, J., et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil, 22, 2010 1069-e281.
21. 21 McCallum, R.W., Cynshi, O., Investigative Team. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther 26 (2007), 1121–1130.
22. 22 Talley, N.J., Verlinden, M., Geenen, D.J., et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 49 (2001), 395–401.
23. 23 Parkman, H.P., Carlson, M.R., Gonyer, D., Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2B randomized study. Clin Gastroenterol Hepatol 13 (2015), 1256–1263.